Cantel Medical to pony up $60M+ for endoscope reprocessing company

In another endoscope-related deal, Cantel Medical will buy Germany's BHT Group, which sells endoscope storage systems and automatic endoscope reprocessing systems.

Cantel Medical has agreed to acquire BHT Hygienetechnik Holding GmbH (BHT Group) for about $60.8 million. The German company markets automated endoscope processing technology.

In the deal, Cantel will pick up endoscope storage and drying systems and flexible endoscope repair services, as well as automatic endoscope reprocessors. The deal is expected to close at the end of August.

"The addition of BHT Group will enable us to become the market leader in automated endoscope reprocessors in Germany," said Cantel Medical CEO Jorgen Hansen. "We're excited to combine BHT's expertise and the talent with our Cantel Germany operations. Together we will deliver a market leading portfolio of endoscopy products and services to our customer."


Like this story? Subscribe to FierceBiotech!

Biopharma is a fast-growing world where big ideas come along every day. Our subscribers rely on FierceBiotech as their must-read source for the latest news, analysis and data in the world of biotech and pharma R&D. Sign up today to get biotech news and updates delivered to your inbox and read on the go.

This isn’t Cantel’s first endoscope-related deal. In 2015, the New Jersey-based company inked a deal to buy U.K.-based Medical Innovations Group for $79.5 million. It acquired an endoscope storage system and endoscopy consumables in the transaction.

The Medical Innovations Group deal came after the FDA highlighted that the design of some duodenoscopes—a type of endoscope—prevented them from being cleaned properly and contributed to the spread of infectious bacteria. At the time, an internal investigation at UCLA's Ronald Reagan Medical Center showed that two medical duodenoscopes may have transmitted a deadly infection between patients, even though the scopes were sterilized to the manufacturer's standards.


Suggested Articles

What the NASH field needs, says Genfit CEO Pascal Prigent, is something like the Hb1Ac test for diabetes.

Dubbed “Project Nightingale,” the efforts were announced amid concerns and federal inquiries into the data’s safekeeping and patient consent for use.

Exact Sciences received an FDA breakthrough designation for its liver cancer blood test as it finalized its $2.8 billion merger with Genomic Health.